DLL3 and small cell lung carcinoma: Tarlatamab (AMG 757) is a half-life extended BiTE designed to specifically bind DLL3 on cancer cells and CD3 on T cells, resulting in T-cell-dependent killing of cancer cells with DLL3 expression in the SCLC patient-derived xenograft models [216].